Controlled release hydrophilic matrix tablet formulations of isoniazid: Design and in vitro studies

AAPS PharmSciTech

Volumn 9, Issue 4, 2008, Pages 1171-1178

  Hiremath, Praveen S ^a,b   Saha, Ranendra N ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b Pharmaceutics International Inc   (United States)

Author keywords

Controlled release; Dissolution; Rifampicin and isoniazid; Spectroscopy

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; ISONIAZID; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG DESIGN; DRUG DIFFUSION; DRUG GRANULATION; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHILICITY; IN VITRO STUDY; PH; REPRODUCIBILITY; TABLET FORMULATION; TABLET HARDNESS; VISCOSITY; CHEMISTRY; DELAYED RELEASE FORMULATION; HALF LIFE TIME; SOLUBILITY; TABLET; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTITUBERCULAR AGENTS; DELAYED-ACTION PREPARATIONS; HALF-LIFE; ISONIAZID; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 63649143161     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9159-0     Document Type: Article

References (32)

1. M. V. S. Verma, A. M. Kaushal, A. Garg, and S. Garg. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. Am. J. Drug Deliv. 2:43-57 (2004).
2. K. S. Soppimath, A. R. Kulkarni, and T. M. Aminabhavi. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: characterization and release kinetics of microspheres and tableted microspheres. J. Microencapsul. 18:397-409 (2001).
3. M. Velasco, J. L. Ford, P. Rowe, and A. R. Rajabi-Siahboomi. Influence of drug: hyYdroxypropyl methylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC matrices. J. Control. Release. 57:75-85 (1999).
4. C. I. Varghas, and E. S. Ghaly. Kinetic release of theophyline from hydrophilic swellable matrices. Drug Dev. Ind. Pharm. 25:1045-1050 (1999).
5. L. Maggi, E. O. Machiste, M. L. Torre, and U. Conte. Formulation of biphasic release tablets containing slightly soluble drugs. Eur. J. Pharm. Biopharm. 48:37-42 (1999).
6. D. A. Alderman. A review of cellulose ether in hydrophilic matrices for oral controlled release dosage forms. Int. J. Pharm. Technol. Prod. Manuf. 5:1-9 (1984).
7. K. V. Ranga Rao, K. Padmalatha Devi, and B. Buri. Cellulose matrices for zero-order release of soluble drugs. Drug Dev. Ind. Pharm. 14:2299-2320 (1988).
8. C. J. Shishoo, S. A. Shah, I. S. Rathod, and S. S. Savale. Impaired bioavailability of rifampicin from fixed dose combination (FDC) formulations with isoniazid. Indian J. Pharm. Sci. 63:443-449 (2001).
9. G. L. Mandell, and W. A. Petri Jr. Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th Ed, McGraw-Hill Health Professional Division, New York, 2001, pp. 1155-1174.
10. T. Schaberg, K. Rebhan, and H. Lode. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 9:2026-2030 (1996).
11. W. J. Burman, K. Gallicano, and C. Peloquin. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341 (2001).
12. L. Eidus, and M. M. Hodgkin. A new isoniazid preparation designed for moderately fast and "fast" metabolizers of the drug. Arzneim-Forsch. (Drug Res.). 25:1077-1080 (1975).
13. G. A. Ellard, P. T. Gammon, S. Laksminarayan, W. Fox, V. R. Aber, D. A. Mitchison, K. M. Citron, and R. Tall. Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis. Lancet. 1:340-343 (1972).
14. M. Dutt, and G. K. Khuller. Sustained release of isoniazid from a single injectable dose of poly(dl -lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int. J. Antimicrob. Agents. 17:115-122 (2001).
15. O. F. Bulut, Y. Capan, S. Kas, L. Oner, and A. A. Hincal. Sustained release isoniazid tablets. I - Formulation and in vitro evaluation. Farmaco. 44:739-752 (1989).
16. B. B. Barik, S. Ray, N. Goswami, B. K. Gupta, and L. K. Ghosh. Preparation and in vitro dissolution of isoniazid from ethylcellulose microcapsules. Acta Pol. Pharm. 58:65-68 (2001).
17. A. A. Bosela, M. M. el-Sayed, and M. I. Mahmoud. Preparation of targeted isoniazid microspheres. Boll. Chim. Farm. 137:77-81 (1998).
18. R. M. Lucinda-Silva, and R. C. Evangelist. Microspheres of alginate chitosan containing isoniazid. J. Microencapsulation. 20:145-52 (2003).
19. S. K. Mehta, G. Kaur, and K. K. Bhasin. Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: Effect on microstructure and physical parameters. Pharm Res. 25 1, 227-36 (2008).
20. S. P. Hiremath, and R. N. Saha. Design and study of rifampicin oral controlled release formulations. Drug Deliv. 11:311-317 (2004).
21. P. S. Hiremath, and R. N. Saha. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release. Drug Delivery. 15 3, 159-168 (2008).
22. P. S. Hiremath, and R. N. Saha. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: Design and in-vitro evaluations. Int. J. Pharm. 362 1-2:118-125 (2008).
23. M. Lindenberg, S. Kopp, and J. B. Dressman. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutical classification system. Eur. J. Pharm. Biopharm. 58:265-278 (2004).
24. P. L. Ritger, and N. A. Peppas. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release. 5:37-42 (1987).
25. P. Costa, and J. M. S. Lobo. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:123-133 (2001).
26. M. Levina, and A. R. Rajabi-Siahboomi. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J. Pharm. Sci. 93:2746-2754 (2004).
27. P. Gao, J. W. Skoug, P. R. Nixon, T. R. Ju, N. L. Stemm, and K. C. Sung. Swelling of hydroxypropyl methylcellulose tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J. Pharm. Sci. 85:732-740 (1996).
28. P. I. Lee, and N. A. Peppas. Prediction of polymer dissolution in swellable controlled release systems. J. Control. Release. 6:207-215 (1987).
29. J. L. Ford, M. H. Rubinstein, and J. E. Hogan. Formulation of sustained release promethazine hydrochloride tablets using hydroxypropyl methylcellulose matrices. Int. J. Pharm. 24:327-338 (1985).
30. L. C. Feely, and S. S. Davis. Influence of surfactants on drug release from hydroxypropylmethylcellulose matrices. Int. J. Pharm. 41:83-90 (1988).
31. J. Siepmann, H. Kranz, R. Bodmeier, and N. A. Peppas. HPMC-matrices for controlled drug delivery: A new model combining diffusion, swelling, and dissolution mechanisms and predicting release kinetics. Pharm. Res. 16:1748-1756 (1999).
32. J. Siepmann, and N. A. Peppas. Hydrophilic matrices for controlled rug delivery: An improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model). Pharm. Res. 17:1290-1298 (2000).